Atlas Trials

Neoplasms, Ovarian

16 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Neoplasms, Ovarian

RecordFirmDate
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer (NCT05059782)Xi'an Jiaotong University2021-10-10
Study of ESG401 in Adults With Solid Tumors (NCT04892342)Shanghai Escugen Biotechnology Co., Ltd2021-09-14
Urinary Human Papilloma Virus Test in the General Population in Brittany (NCT03598946)University Hospital, Brest2021-04-29
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer (NCT03162562)CanariaBio Inc.2017-05-30
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer (NCT02582931)Washington University School of Medicine2015-12-02
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (NCT02432378)Roswell Park Cancer Institute2015-09-04
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer (NCT02055690)The Christie NHS Foundation Trust2014-09-01
Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine (NCT02178670)Fuda Cancer Hospital, Guangzhou2014-06-01
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (NCT01815294)Janssen Research & Development, LLC2013-05-01
Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women (NCT01227928)GlaxoSmithKline2010-09-01
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer (NCT00659178)GlaxoSmithKline2008-06-18
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors (NCT00561795)GlaxoSmithKline2007-09-01
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer (NCT00281632)GlaxoSmithKline2006-03-01
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer (NCT00316173)GlaxoSmithKline2005-03-01
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer (NCT00061308)GlaxoSmithKline2002-12-01

Track Neoplasms, Ovarian automatically

Every clearance here is in the API, with alerts when new ones post.